Leadership changes at Fulcrum Therapeutics, Inc. (2026)

Appointed: Alan Musso, effective 2026-08-07

In light thereof, on August 9, 2026, Fulcrum's Board of Directors appointed Alan Musso, Fulcrum's chief financial officer and principal financial officer, as principal accounting officer, effective August 7, 2026, upon Mr. Tourangeau's departure.

Also stated in this filing

• Fulcrum and Mr. Tourangeau have agreed that his tenure in such roles will end on August 7, 2026.
• Mr. Musso will not receive any additional compensation in connection with this appointment.

Departing: Greg Tourangeau, Vice President, Finance

On June 10, 2026, Fulcrum and Greg Tourangeau, Fulcrum's Vice President, Finance and principal accounting officer, mutually agreed that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed between Mr. Tourangeau and Fulcrum.

Also stated in this filing

• As previously disclosed, on May 31, 2026, the board of directors, or Board, of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum's operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease.
• In addition, the compensation committee of the Board also approved the provision of "Change in Control" benefits for all remaining employees at the Vice President and above level, if the employee is terminated other than for "Cause" within six months immediately prior to a "Change in Control" and provided that the Board or Chief Executive Officer determines that he or she has satisfied his or her transitional duties.
• Fulcrum intends to file copies of the amendments to the employment agreements as exhibits to its quarterly report on Form 10-Q for the period ending June 30, 2026.
• Mr. Tourangeau's departure is not the result of any disagreement with the Company regarding its financial statements, accounting policies, internal controls, disclosure controls, or any other accounting or financial reporting matter.

Appointed: Josh Lehrer, Director

On April 23, 2026, the board of directors, or the Board, of Fulcrum, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Josh Lehrer as a member of the Board, with immediate effect.

Appointed: Josh Lehrer

Mr. Lehrer was appointed to serve on the Science & Technology Committee.

Departing: Alan Musso

On April 23, 2026, Alan Musso notified Fulcrum of his intent to retire as chief financial officer and treasurer (and as principal financial officer).

Also stated in this filing

• Mr. Lehrer will serve as a Class III director with a term expiring at Fulcrum's 2028 annual meeting of stockholders and thereafter until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
• The Board has determined that Mr. Lehrer is "independent" as contemplated by the Nasdaq Stock Market and other governing laws and applicable regulations.
• Pursuant to the terms of the indemnification agreement, Fulcrum may be required, among other things, to indemnify Mr. Lehrer for certain expenses (including attorneys' fees), judgments, fines and settlement amounts actually and reasonably incurred by him in any action or proceeding arising out of his service as a member of the Board.
• Mr. Musso will remain in his current role until a successor is named and has agreed to serve as a consultant thereafter to assist with an orderly transition.
• Fulcrum intends to conduct an executive search to identify a replacement for Mr. Musso.
• In recognition of Mr. Musso's service and agreement to remain in his current role while his successor is identified and to be available to advise Fulcrum to ensure a smooth transition, Mr. Musso's retirement will be treated as an ending pursuant to Section 7(b) of his employment agreement dated August 7, 2023, or the Employment Agreement.